

Corporate Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi- 110019 (India) Tel: +91-11-47589500 (30 Lines) /26221811/26418182 Email: info@shivalikrasayan.com

> website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041

> > Date: 13.08.2021

Ref: STEX/OUTCOME/2021-22

BSE Limited

Department of Corporate Services-Listing
PJ Towers, Dalal Street

Mumbai- 400001

Company No.: 539148

Sub.: Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2021.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2021 as **Annexure-A** and
- b) Unaudited Segment-wise Revenue, Results, Assets and Liabilities of the Company, both Standalone and Consolidated, for the Quarter ended 30th June, 2021; as **Annexure-B** and
- c) Limited Review Report from Rai Qimat & Associates, chartered Accountant on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-C**

Further Board of Directors at their meeting approved the following resolutions:

- a) Approved draft Annual Report for the financial year 2020-21.
- b) The 43<sup>rd</sup> AGM of the Company will be held on Monday the September 27, 2021 at 11.00 A.M. at Hotel Saffron Leaf, GMS Road Dehradun, Uttarakhand-248146.
- c) Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Monday, September 20, 2021 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialised form) to cast their vote electronically from Friday, September 24, 2021 to Sunday, September 26, 2021.
- d) In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Rs. 0.50 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2020-21. The aforesaid register will remain close from Tuesday, September 21, 2021 to Monday, September 27, 2021 (both days inclusive)

The meeting of the Board of Directors commenced 04.15 p.m. and concluded at 05.50 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2021, as approved by the Board, will also be available on the Company's website www.shivalikrasayan.com.

This is for your information and records.

Thanking You.

Yours faithfully, For Shivalik Rasavan Limited

Parul Choudhar

Company Secretary & Compliance Officer

ACS: 34854



### Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007 CIN: L24237UR1979PLC005041

E-mail: cs@shivalikrasayan.com, www.shivalikrasayan.com

Un-Audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June 2021

PAR		T		. <del> </del>	(Seggi Comment				per share data)
			Stand	alone	n, så.	e de Assacia especial de la colo		solidated	
			er Ended	<u> , marakiwa an was</u>	Year Ended		Quarter Ended		Year Ended
	Particulars	3 Months	3 Months	3 Months		3 Months	3 Months	3 Months	
		Ended	Ended	Ended	31/03/2021	Ended	Ended	Ended	31-03-2021
		30/06/2021	31/03/2021	30/06/2020		30/06/2021	31/03/2021	30/06/2020	
	and the state of t	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1	Income from operations								
	(a) Net Sales/income from operations	2,285.70	2,208.04	1,822.66	8,486.60	5,038.74	4,331.92	4,601.01	19,758.2
	(b) Other Income	0.10	1.73	12.85	37.79	7.97	55.45	21.26	13,738.2
	Total Revenue	2,285.80	2,209.77	1,835.51	8,524.39	5,046.70	4,387.37	4,622.27	19,871.4
2	Expenses	,	des o a final and			3,5 75.70	7,507.37	7,022.27	15,0/1.4
	a) Cost of Material Consumed	921.42	811.82	1,035.15	3,713.79	2,145.94	1,901.90	2,833.32	10 555 0
	b) Purchase of Stock-in-Trade	3	-		3,713.73	27240104	1,301.30	2,033.32	10,555.8
	c) Changes in inventory of Finished Goods and Work in					_	•	-	•
	Progress	10.52	(116.90)	20.53	28.82	13.91	(235.17)	58.63	132.8
	d) Employees Benefits Expenses	324.25	372.63	247.44	1,218.18	616.72	605.71	467.37	2440.0
	e) Finance Cost	31.12	13.54	1.52	51.07	35.54		467.37	2,118.6
	f) Depreciation and Amortisation Expenses	127.13	169.23	95.45	606.27		49.56	25.47	157.4
	g) Other expenses	381.07	479.04	95.45 278.76		260.10	210.69	164.69	858.2
	Total Expenses				1,652.91	1,009.64	964.21	592.30	3,155.6
	Total Expenses	1,795.52	1,729.37	1,678.84	7,271.04	4,081.85	3,496.91	4,141.78	16,978.6
3	Profit/(Loss) before Exceptional Items & Tax (1-2)	490.28	480.39	156.67	1,253.35	964.86	890.45	480.49	2,892.7
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Year)	-	· •		-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3-4)	490.28	480.39	156.67	1,253.35	964.86	890.45	480.49	2,892.7
6	Tax Expenses								
	Current Year	80.31	(3.28)	43.59	211.75	146.34	37.09	140.52	626.2
	MAT Credit Entitlement	(80.31)	3.28	(43.59)	(211.75)	(80.31)	37.03	(43.59)	
	Deferred Tax Liability	(8.00)	(5.04)	(5.25)	(14.21)	(14.59)	(0.03)		(211.7
	Total Tax Expenses	(8.00)	(5.04)	(5.25)	(14.21)	51.44		(2.77)	(2.2
7	Net Profit/Loss for the period (5-6)	498.28	485.43	161.93	1,267.55	913.42	40.34	94.16	412.2
8	Other Comprehensive Income	750.20	705,45	101.93	1,207.35	915.42	850.11	386.33	2,480.5
	Item that will not be reclassified to Profit & Loss		÷		-	-	-	-	-
	Total Comprehensive income Net of Tax	498.28	485.43	161.93	1,267.55	913.42	850.11	386.33	2,480.5
9	Total Comprehensive income for the Period (7+8)	498.28	485.43	161.93	1,267.55	913,42	850.11	386.33	2,480.5
					2,207.33	313.42	030.11	300.33	2,480.5
10	Net Profit/ (loss) attribulable to	1			ļ	]			
	a) Controlling Interest	498.28	485.43	161.93	1,267.55	671.77	657.46	350.54	
ı	b) Non Controlling Interest	750.20	403.43	101.93	1,207.33		657.10	250.61	1,774.4
			1		1	241.65	193.01	135.72	706.0
11	Paid-up equity share capital (Rs.5/- per share)	688.96	688.96	600.00	500.05	600.00	600.57	****	
12	Earning Per Share (Rs.)	06.50	96.880	688.96	688.96	688.96	688.96	688.96	688.9
	(a) Basic	2.5				. 1		1	
		3.62	3.52	1.18	9.20	4.88	4.77	1.82	12.8
	(b) Diluted	3.62	3.52	1.18	9.20	4.88	4.77	1.82	12.8

#### NOTES:

- 1 The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.08.2021.
- 2 The figures are regrouped in previous year also, wherever considered necessary.
- 3 The company operates in business segment viz Agro Chemical, Pharma API & Pharma Formulations.
- 4 The Earning Per Share has been calculated as per Ind AS-33.
- 5 Limited Review Report has been carried out by the Statutory Auditors for the above period.

For & on behalf of Board of Directors

्र कुर Shivalik Rasayan Limited

(Rahul Bishnoi) Chairman

Place: New Delhi Dated: 13.08.2021



# Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007 CIN: L24237UR1979PLC005041

E-mail: cs@shivalikrasayan.com, www.shivalikrasayan.com

	June 2021	
	30th	
	ded or	
	er en	
	Quart	
	or the	
•	ities fo	
	liabil	
	ts and	
	, asse	
•	results	_
	evenue, 1	
	wise r	
	gment	
	ed seg	
	olidat	
	Cons	
	lone &	
	tanda	
	lited S	
	Jn-Auc	

Segment revenue   Authority	N	CI No Particulare		Change	940			Ctendalone Commercial	Tana anne	
Segment revenue   Segment re				ממוממ	ione			Consoli	dated	
Segment revenue   Simonthis	ass.			Quarter Ended		Year Ended		Quarter Ended		Year Ended
Segment revenue   30,066/2021   31,031/2021   30,066/2021   31,031/2021   30,066/2021   31,031/2021   30,066/2021   31,031/202			3 Months	3 Months	3 Months	31/03/2021	3 Months	3 Months Ended	3 Months Ended	31/03/2021
Authority   Auth			Ended	Ended	Ended		Ended	31/03/2021	30/06/2020	-
Segment revenue         Unaudited         Audited         Unaudited         Audited         Unaudited         Audited         Unaudited         Audited         Unaudited         Audited         Unaudited         Audited         Unaudited         Unau			30/06/2021	31/03/2021	30/06/2020		30/06/2021			
Segment twente         2.283.57         2,069.97         1,822.66         8,344.01         2,233.57         2,069.97         1,822.66         2,133.67         2,133.68         1,822.66         2,133.67         2,133.68         2,132.68         2,132.68         2,133.67         2,133.67         1,822.66         2,133.67         2,133.68		The state of the s	Unaudited	Audited	Unaudited	Audited	Unandited	Audited	Unaudited	Audited
A Agrochemicals Contained by A Agrochemicals Contained by	H	Segment revenue	en found				-			
D. Charma formulation D. Charma formulation D. Unallocated during travenue D. Unallocated during predient (API) D. Unallocated during facefient (API) D. Unallocated facefient (API)		A. Agrochemicals	2,283.57	2,069.97	1,822.66	8,344.01	2,283.57	2,069.97	1,822.66	8,486.60
C. Pharma Formulation         2,28,08         2,123.88         2,173.88         2,173.88         2,173.83         11           Total Revenue         2,285.70         2,208.04         1,822.66         8,486.60         5,638.74         4,331.33         4,601.01         15           Segment results         Ageochemicals         7,833.33         608.17         327.62         2,093.53         783.33         608.17         327.62         2,093.53         783.33         4,601.01         15           B. Active Pharma Ingredient (API)         (261.92)         (111.24)         (116.43)         (118.44)		B. Active Pharma Ingredient (API)	2.13	138.08	•	142.60	2.13	138.08		•
D. Unallocated other operating revenue         2,285.70         2,208.04         1,822.66         8,486.60         5,038.74         4,331.33         4,601.01         11           Total Revenue         1,282.6         2,208.04         1,822.6         2,093.53         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         2,093.63         783.33         608.17         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.62         327.77         327.77         327.77         327.62         327.77         327.64         490.58         347.77         327.44         490.58         327.46         480.39         480.39         480.39		C. Pharma Formulation	1	•		•	2,753.03	2,123.88	2,778.35	11.271.61
Total Revenue   2,288.70   2,208.04   1,822.66   5,088.74   4,331.93   4,601.01   13     Segment results   2,888.74   1,822.61   1,822.61   1,822.61   1,822.61   1,822.61   1,822.61   1,822.61   1,822.61   1,822.61   1,822.61   1,822.81   1,822.81   1,823.81   1		D. Unallocated other operating revenue	t	•	•	•	1	•		
Segment results         788.33         668.17         327.62         2,099.53         783.33         6608.17         327.62         2         2         4,60.93         7,83.33         6608.17         327.62         2         4,60.93         7,83.33         6608.17         327.62         2         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         347.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         3,60.77         3         4,60.93         4,60.93		Total Revenue	2,285.70	2,208.04	1,822.66	8,486.60	5,038.74	4,331.93	4,601.01	19,758.21
A. Agrochemicals         A. Agrochemicals         783.33         608.17         327.62         2,093.53         783.33         608.17         327.62         2,093.53         783.33         608.17         327.62         2,093.53         783.93         783.93         327.62         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.72         327.42         327.22         327.22         327.22         327.22         327.2	7	Segment results								
B. Active Pharma Ingredient (API)         (26132)         (114.24)         (169.43)         (789.12)         (261.92)         (114.24)         (169.43)         777         1           C. Pharma Formulation         Sub That Sommulation         S21.41         493.93         158.19         1,304.42         1,000.39         446.09         337.77         1           Less: Unallocable expenditure net of unallocable income         31.12         13.54         1,523.35         964.86         890.46         480.49         250.96         3           Profit Lestore exceptional items and tax         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49         250.96           Exceptional items         Profit Lestore exceptional items and tax         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49         250.40           Exceptional items         Profit Lestore exceptional items         490.28         480.39         156.57         1,253.35         964.86         890.46         480.49         250.40         480.49         480.49         250.40         480.49         480.49         250.40         480.49         250.40         250.40         250.40         250.40         250.40         250.40 <t< td=""><th></th><td>A. Agrochemicals</td><td>783.33</td><td>608.17</td><td>327.62</td><td>2,093.53</td><td>783.33</td><td>608.17</td><td>327.62</td><td>2.093.53</td></t<>		A. Agrochemicals	783.33	608.17	327.62	2,093.53	783.33	608.17	327.62	2.093.53
C. Pharma Formulation         521.41         493.93         158.19         1,304.42         1,004.39         446.09         34.77         7           Less: Unallocable expenditure net of unallocable expenditure and tax         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49         25.47           Profit/Loss) before tax         (8.00)         (5.05)         (5.05)         (14.21)         51.44         40.34         94.16         25.46           Net Profit/Loss) before tax         (8.00)         (5.05)         (5.05)         (14.21)         51.44         40.34         94.16         25.44         480.49         25.59         485.48         880.46         480.49         25.59         485.48         880.46         880.46         35.32         25.44         25.44         40.34         35.24         35.24         35.24         35.24         35.24         35.24		B. Active Pharma Ingredient (API)	(261.92)	(114.24)	(169.43)	(789.12)	(261.92)	(114.24)	(169.43)	(789.12)
Sub Total         521.41         493.39         158.19         1,304.42         1,000.39         940.02         505.96         3           LessFinance costs         LessFinance costs         11.52         51.07         35.54         49.56         25.47         3         2 <th></th> <td>C. Pharma Formulation</td> <td>•</td> <td>•</td> <td>ı</td> <td>ı</td> <td>478.98</td> <td>446.09</td> <td>347.77</td> <td>1,745.80</td>		C. Pharma Formulation	•	•	ı	ı	478.98	446.09	347.77	1,745.80
Less: Finance costs   Less: Finance costs   Less: Finance costs   Less: Comparison of the standard of the st		Sub Total	521.41	493.93	158.19	1,304.42	1,000.39	940.02	505.96	3,050.22
Less: Unallocable expenditure net of unallocable   Less: Unallocable expenditure net of unallocable expenditure net of unallocable expenditure net of unallocable   Less: Unallocated		Less:Finance costs	31.12	13.54	1.52	51.07	35.54	49.56	25.47	157.46
Profit before exceptional items and tax		Less: Unallocable expenditure net of unallocable	in the second		A CAMP	6.00.43			4	
Profit before exceptional items         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49           Exceptional items         Exceptional items         Exceptional items         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49           Profit/(Loss) before tax         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49           I Less: Tax Expenses         (8.00)         (5.05)         (5.25)         (4.21)         51.44         40.34         94.16           Net Profit/(Loss) for the period/year         498.28         485.43         161.92         1,267.55         913.42         850.12         385.12         386.33           Segment assets         7,389.92         6,816.45         3,599.49         6,816.45         7,389.92         6,816.45         3,599.49         1,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.63         1,047.93         1         1,047.93         1         1,047.93         1,047.93         1         1,047.93         1,047.93         1,047.93	·	income		•	•	•	,	•	•	
Exceptional Items         Exercises         480.39         156.67         1,253.35         964.86         890.46         480.49			490.28	480.39	156.67	1,253.35	964.86	890.46	480.49	2,892.75
Profit/(Loss) before tax         490.28         480.39         156.67         1,253.35         964.86         890.46         480.49         480.49           Less: Tax Expenses         (8.00)         (5.05)         (5.25)         (14.21)         51.44         40.34         94.16           Net Profit/(Loss) for the period/year         488.28         485.43         161.92         1,267.55         913.42         850.12         386.33           Segment assets         7,389.92         6,816.45         3,599.49         6,816.45         7,389.92         6,816.45         3,599.49         6,816.45         3,599.49         3,599.49         6,816.45         10,077.59         9,432.65         1           C. Pharma formulation         D. Unallocated         16,888.64         16,894.04         13,032.14         16,894.04         36,911.30         36,246.87         24,080.07         3           Segment liabilities         2,251.71         2,396.37         1,284.89         2,356.37         2,251.71         2,396.37         1,284.89         2,356.37         2,308.39         36,246.87         2,080.07         3           A. Agrochemicals         B. Active Pharma Ingredient (API)         308.93         426.13         322.46         36,911.30         36,246.87         2,703.88		Exceptional Items		-	•					-
Net Profit/(Loss) for the period/year         (8.00)         (5.05)         (5.25)         (14.21)         51.44         40.34         94.16           Net Profit/(Loss) for the period/year         498.28         485.43         161.92         1,267.55         913.42         850.12         386.33           Segment assets         A. Agrochemicals         7,389.92         6,816.45         3,599.49         6,816.45         7,389.92         6,816.45         3,599.49         6,816.45         7,389.92         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         10,077.59         9,432.65         1         1,284.89         1,289.40         36,911.30         36,246.87		Profit/(Loss) before tax	490.28	480.39	156.67	1,253.35	964.86	890.46	480.49	2,892.75
Net Profit/(Loss) for the period/year         498.28         485.43         161.92         1,267.55         913.42         850.12         386.33           Segment assets         A. Agrochemicals         A. Agrochemicals         7,389.92         6,816.45         3,599.49         6,816.45         3,599.49         3,599.49           B. Active Pharma Ingredient (API)         9,498.72         10,077.59         9,432.65         10,077.59         9,432.65         11,047.93         11,049.93         11,049.93         11,049.93         11,049.93         11,049.93         11,049.93         1,0407.35 <t< td=""><th></th><td>Less: Tax Expenses</td><td>(8.00)</td><td>(5.05)</td><td>(5.25)</td><td>(14.21)</td><td>51.44</td><td>40.34</td><td>94.16</td><td>412.25</td></t<>		Less: Tax Expenses	(8.00)	(5.05)	(5.25)	(14.21)	51.44	40.34	94.16	412.25
A. Agrochemicals         7,389.92         6,816.45         3,599.49         6,816.45         7,389.92         6,816.45         3,599.49         7,389.92         6,816.45         3,599.49         7,389.92         6,816.45         3,599.49         7,389.92         6,816.45         3,599.49         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         11,047.93         1           C. Pharma Formulation         D. Unallocated         16,888.64         16,894.04         13,032.14         16,894.04         36,211.30         36,246.87         24,080.07         3           Segment liabilities         A. Agrochemicals         2,251.71         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         2,296.37         2,296.37         2,296.37         2,296.37         2,296.37         2,296.37         2,296.38         2,296.38         2,296.38         2,296.38         2,296.38         2,222.49		Net Profit/(Loss) for the period/year	498.28	485.43	161.92	1,267.55	913.42	850.12	386.33	2,480.50
A. Agrochemicals         7,389.92         6,816.45         3,599.49         6,816.45         7,389.92         6,816.45         3,599.49         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         10,077.59         9,432.65         11,047.93         11,047.93         1           C. Pharma Formulation         D. Unallocated         16,888.64         16,894.04         13,032.14         16,894.04         36,211.30         36,246.87         24,080.07         3           Segment liabilities         2,251.71         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,703.38         2,703.38         2,703.38         <	m	Segment assets								
B. Active Pharma Ingredient (API)         9,498.72         10,077.59         9,432.65         10,077.59         9,498.72         10,077.59         9,432.65         1           C. Pharma Formulation         D. Unallocated         20,022.66         19,352.83         11,047.93         1           D. Unallocated         Total         16,888.64         16,894.04         13,032.14         16,894.04         36,211.30         36,246.87         24,080.07         3           Segment liabilities         2,251.71         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         2,251.71         2,396.37         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38		A. Agrochemicals	7,389.92	6,816.45	3,599.49	6,816.45	7,389.92	6,816.45	3,599.49	6,816.45
C. Pharma Formulation         C. Pharma Formulation         20,022.66         19,352.83         11,047.93         1           D. Unallocated         10,0410cated         16,888.64         16,894.04         13,032.14         16,894.04         36,246.87         24,080.07         3           Segment liabilities         2,251.71         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         2,396.37         1,284.89         2,396.37         2,396.37         1,284.89         2,396.37         2,396.37         1,284.89         2,396.37		B. Active Pharma Ingredient (API)	9,498.72	10,077.59	9,432.65	10,077.59	9,498.72	10,077.59	9,432.65	10,077.59
D. Unallocated         D. Unallocated         16,888.64         16,894.04         15,894.04         36,246.87         24,080.07         3           Segment liabilities         2,251.71         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         2,396.37         1,284.89         2,396.37         2,793.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,703.38         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.73         2,310.7		C. Pharma Formulation	,	1	•	,	20,022.66	19,352.83	11,047.93	19,352.83
Total         Total         16,888.64         16,894.04         13,032.14         16,894.04         36,246.87         24,080.07         3           Segment liabilities         A. Agrochemicals         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         2,396.37         1,284.89         426.13         308.93         426.13         322.46         426.13         308.93         426.13         322.46         426.13         308.93         426.13         322.46         426.13         308.93         426.13         322.46         426.13         308.93         426.13         322.46         4330.55         2,703.38           D. Unallocated         2,560.64         2,822.49         1,607.35         2,822.50         8,248.68         7,153.05         4,310.73		D. Unallocated	•	•	•	•	•	,	•	•
ent liabilities 2,251.71 2,396.37 1,284.89 2,396.37 2,251.71 2,396.37 1,284.89 rochemicals 308.93 426.13 322.46 426.13 308.93 426.13 322.46 arma Formulation 2,560.64 2,822.49 1,607.35 2,822.50 8,248.68 7,153.05 4,310.73	4	Total	16,888.64	16,894.04	13,032.14	16,894.04	36,911.30	36,246.87	24,080.07	36,246.87
rochemicals         2,251.71         2,396.37         1,284.89         2,396.37         2,251.71         2,396.37         1,284.89           sive Pharma Ingredient (API)         308.93         426.13         322.46         426.13         308.93         426.13         322.46           arma Formulation         5,688.04         4,330.55         2,703.38         2,703.38           allocated         2,560.64         2,822.49         1,607.35         2,822.50         8,248.68         7,153.05         4,330.73		Segment liabilities							-	
tive Pharma Ingredient (API)         308.93         426.13         322.46         426.13         308.93         426.13         322.46           arma Formulation         5,688.04         4,330.55         2,703.38         2,703.38         2,703.38           allocated         2,560.64         2,522.49         1,607.35         2,822.50         8,248.68         7,153.05         4,310.73		A. Agrochemicals	2,251.71	2,396.37	1,284.89	2,396.37	2,251.71	2,396.37	1,284.89	2,396.37
arma Formulation 5,688.04 4,330.55 2,703.38 2,310.73 2,520.54 2,520.64 2,822.49 1,607.35 2,822.50 8,248.68 7,153.05 4,310.73		B. Active Pharma Ingredient (API)	308.93	426.13	322.46	426.13	308.93	426.13	322.46	426.13
allocated 2,560.64 2,822.49 1,607.35 2,822.50 8,248.68 7,153.05 4,310.73	·	C. Pharma Formulation	•	1	•	,	5,688.04	4,330.55	2,703.38	4,330.55
2,560.64 2,822.49 1,607.35 2,822.50 8,248.68 7,153.05 4,310.73		D. Unallocated	•	•			•		,	
		Total	2,560.64	2,822.49	1,607.35	2,822.50	8,248.68	7,153.05	4,310.73	7,153.05

(Rahul Bishnoi) Chairman For Broughsehalf of Board of Directors કે દ્વાપ્યાં Rasayan Limited <u>CATU</u>

Place: New Delhi Dated:13.08.2021

# **RAI QIMAT & ASSOCIATES**

CHARTERED ACCOUNTANTS



INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To

The Board of Directors, Shivalik Rasayan Ltd. Village Kolhupani, P.O. Chandanwari, Dehradun-248007

We have reviewed the accompanying statement of unaudited financial results of M/s Shivalik Rasayan Limited having its Corporate Office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and three months ended June 30, 2021 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat& Associates Chartered Accountants

Partner ership Number: 013452

(Membership Number: 013152C) UDIN: 210808574444EJ1385

Place: Gurugram Date: 13.08.2021



## **RAI QIMAT & ASSOCIATES**

CHARTERED ACCOUNTANTS



INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To

The Board of Directors, Shivalik Rasayan Ltd. Village Kolhupani, P.O. Chandanwari, Dehradun-248007

- We have reviewed the Unaudited Consolidated Financial Results of Shivalik Rasayan Limited (the
  "Parent Company"), and the Subsidiary Company for the quarter and three months ended on June
  30, 2021 which are included in the accompanying 'Statement of Consolidated Unaudited Financial
  Results for the quarter ended June 30, 2021 (the "Statement"). The Statement is being submitted
  by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing
  Obligations and Disclosure Requirements) Regulations, 2015, as amended, (the "Listing
  Regulations, 2015").
- 2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
- 4. The Statement includes the results of the Medicamen Biotech Limited (the "Associate" Company)
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

404, 4th Floor, DLF Galleria Phase-IV, Gurugram 122,000, Haryana Tel.: 0124-4087353, Mob.: 9340518507 E-mail: rai.garg@gma

# RAI QIMAT & ASSOCIATES






7. The Statements includes the Group's share of net profit after tax of Rs. 415.13 Lakhs for the quarter ended on June 30, 2021, as considered in the consolidated unaudited financial results, in respect of an associate, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates Chartered Accompants

(Membership Number: 013152C) UDIN: 21080857AAAEJ1385

Place: Gurugram Date: 13.08.2021







Corporate Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi- 110019 (India) Tel: +91-11-47589500 (30 Lines) /26221811/26418182 Email: info@shivalikrasayan.com

website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041

#### **KEY HIGHLIGHTS**

<u>Shivalik Rasayan Limited posts strong Results with a steady revenue</u> <u>growth of 39.64% YoY</u>

Revenue Grows for Q1FY21 grows by 24.53% YoY

EBITDA for Q1FY21 grows by 155.70% YoY

PAT for Q1FY21 grows by 207.72% YoY

Shivalik Rasayan Limited engaged in manufacturing of Organophosphorus based Agrochemicals and Active Pharma Ingredients (APIs) with GMP manufacturing practices. Shivalik Rasayan is the largest producer of international quality Dimethoate Technical and Malathion Technical.

SRL is into following business segments:-

- Agrochemicals- SRL has purchased industrial plot of 50,000 square meters for setting up of manufacturing of KSM, Intermediate, Agro-Chemicals and Specialty Chemicals Unit at Dahej III, Gujarat. The R&D is in the process of development of some Intermediate and Agro- Chemical products which it plans to manufacture at this proposed unit.
- API- The Company has established new pharma API manufacturing facility at PCPIR\* zone in Dahej (Gujarat) which is designed to be a dedicated, state-of-the-art facility for manufacturing General APIs & Oncology APIs and committed to supply high quality APIs to regulatory markets. Our mission is to be a fast-growing and leading Generic APIs and advanced key pharma intermediates Company enabling affordable healthcare worldwide by redefining our healthcare products innovatively with leadership in quality and



Corporate Office: 1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019 (India)
Tel: +91-11-47589500 (30 Lines) /26221811/26418182
Email: info@shivalikrasayan.com

website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041

costs. Presently one Oncology and one General API manufacturing facility are operational.

- SRL Dahej site has received Manufacturing Licenses for Cytoxic & General API from Gujarat State FDCA.
- 5 Oncology API products and 2 General API products have been validated on site till date. Also, SRL has received WHO- GMP Certificate in year 2021 for 2 Oncology and 1 General API products.

#### **CAPEX HIGHLIGHTS**

- ✓ SRL is raising funds through Preferential Issue for setting up of Agro- Chemicals & Specialty Chemical Plant at GIDC Dahej III, Gujarat and other business-related requirements including but not limited to funding business growth, capital expenditure, expansion, exploring new initiatives and for other general corporate purposes.
- ✓ As per the guidelines SRL is eligible to be listed on National Stock Exchange now, therefore we are planning to get listed on NSE in current fiscal year.

